Below are the most recent publications written about "Watchful Waiting" by people in Profiles.
-
Cooperberg MR, Lin DW, Morgan TM, Chapin BF, Chen RC, Eggener SE. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264.
-
Riad A, Schünemann H, Attia S, Pericic TP, Žuljevic MF, Jürisson M, Kalda R, Lang K, Morankar S, Yesuf EA, Mekhemar M, Danso-Appiah A, Sofi-Mahmudi A, Pérez-Gaxiola G, Dziedzic A, Apóstolo J, Cardoso D, Marc J, Moreno-Casbas M, Wiysonge CS, Qaseem A, Gryschek A, Tadic I, Hussain S, Khan MA, Klugarova J, Pokorna A, Košcík M, Klugar M. COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects. Int J Environ Res Public Health. 2021 07 25; 18(15).
-
Sanford T, Gomella PT, Siddiqui R, Su D, An JY, Bratslavsky G, Ball MW, Linehan WM, Metwalli AR. Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. Urol Oncol. 2021 02; 39(2):134.e1-134.e8.
-
Wang AZ, O’Conno LP, Yerram NK, Long L, Zeng J, Mehralivand S, Harmon SA, Lebastchi AH, Ahdoot M, Gomella PT, Gurram S, Choyke PL, Merino MJ, Shih JH, Wood BJ, Turkbey B, Pinto PA. PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance. J Urol. 2020 12; 204(6):1229-1235.
-
Wood CB, Bigcas JL, Alava I, Bischoff L, Langerman A, Kim Y. Papillary-Type Carcinoma of the Thyroglossal Duct Cyst: The Case for Conservative Management. Ann Otol Rhinol Laryngol. 2018 Oct; 127(10):710-716.
-
Goldberg H, Klaassen Z, Chandrasekar T, Fleshner N. Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer. Curr Opin Urol. 2018 Jan; 28(1):46-54.
-
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 06 08; 376(23):2211-2222.
-
Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM, Wagner AA, Wei JT, Lin DW. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol. 2017 04; 197(4):1026-1033.
-
Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol. 2016 Feb; 195(2):313-20.
-
Ankerst DP, Xia J, Thompson IM, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW. Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol. 2015 Dec; 68(6):1083-8.